Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Baxter International
Baxter launches Baxject II needle-less transfer device for Advate
November 7th, 2006
Baxter Healthcare Corp. announced the availability of Baxject II, an innovative needle-less transfer device designed to make the reconstitution and mixing of hemophilia factor therapies easier, faster and safer (as compared to the original Baxject and needles). Baxject II is the newest convenience feature to be added to Advate [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], the only factor VIII therapy free of blood-based additives. Unlike other devices, Baxject II is compatible with existing injection ports and butterfly sets. "With a busy schedule, mixing an infusion is time consuming," said patient, Ellis Sulser. "The Baxject II...
Source: Drug Law Weekly (2006-11-07)
|
